How India Exports Sulfadoxine to the World

As of March 2026, sulfadoxine is not listed as an approved standalone product in the FDA's Orange Book. However, it is commonly used in combination with pyrimethamine as an antimalarial treatment. The absence of approved Abbreviated New Drug Applications (ANDAs) for sulfadoxine alone indicates limited direct market presence in the United States. This aligns with the export data, which shows no significant shipments of sulfadoxine from India to the U.S. market during the 2022-2026 period.

In the European Union and the United Kingdom, sulfadoxine is utilized in combination therapies for malaria treatment. Medicinal products containing sulfadoxine require marketing authorization from the European Medicines Agency (EMA) or the UK's Medicines and Healthcare products Regulatory Agency (MHRA). Manufacturers must comply with Good Manufacturing Practice (GMP) standards as outlined in Directive 2001/83/EC, which mandates that no medicinal product may be placed on the market without proper authorization. (ema.europa.eu)

Sulfadoxine, in combination with pyrimethamine, is included in the World Health Organization's (WHO) Model List of Essential Medicines, underscoring its importance in treating malaria. The combination is also subject to WHO Prequalification, ensuring that products meet global standards for quality, safety, and efficacy. Pharmacopoeial standards for sulfadoxine are detailed in the United States Pharmacopeia (USP), British Pharmacopoeia (BP), European Pharmacopoeia (EP), and Indian Pharmacopoeia (IP), providing comprehensive guidelines for its quality and formulation.

In India, sulfadoxine is classified under Schedule H of the Drugs and Cosmetics Act, indicating that it is a prescription-only medication. The National Pharmaceutical Pricing Authority (NPPA) regulates the pricing of essential medicines; however, as of March 2026, sulfadoxine is not listed under the Drugs (Prices Control) Order (DPCO), suggesting no specific ceiling price is imposed. For exports, the Directorate General of Foreign Trade (DGFT) mandates a No Objection Certificate (NOC) for certain pharmaceutical products, ensuring compliance with international standards and regulations.

Sulfadoxine's primary patents have expired, allowing for generic production and competition. This has led to a diversified market with multiple manufacturers, as evidenced by the 41 active Indian exporters during the 2022-2026 period. The average Free on Board (FOB) unit price of $15.97 reflects this competitive landscape.

In June 2025, the WHO updated its malaria treatment guidelines, emphasizing the use of sulfadoxine-pyrimethamine in intermittent preventive treatment during pregnancy (IPTp) to reduce maternal and neonatal morbidity. In September 2025, the EMA granted orphan designation to a new antimalarial combination therapy, potentially impacting the market dynamics for existing treatments like sulfadoxine-pyrimethamine. In December 2025, the NPPA conducted a review of essential medicines pricing, though sulfadoxine remained unaffected due to its exclusion from the DPCO list. In February 2026, the CDSCO issued a directive enhancing quality control measures for antimalarial drugs, including sulfadoxine combinations, to ensure compliance with international standards. In March 2026, the DGFT streamlined the export NOC process for pharmaceuticals, aiming to facilitate faster approvals for exporters of sulfadoxine and other essential medicines.

These developments reflect the evolving regulatory landscape for sulfadoxine, highlighting its continued relevance in global malaria treatment protocols and the importance of compliance with international quality and safety standards.

India's pharmaceutical industry, including the production of Sulfadoxine, heavily relies on Active Pharmaceutical Ingredients (APIs) and Key Starting Materials (KSMs) imported from China. This dependency has been highlighted during periods of supply disruptions. For instance, in 2018, environmental regulations led to the shutdown of several Chinese API manufacturers, causing supply shortages and price escalations for Indian pharmaceutical companies. Such events underscore the vulnerability of India's pharmaceutical supply chain to external factors affecting Chinese production.

The Indian government has recognized this risk and, in March 2020, introduced the Production Linked Incentive (PLI) scheme to bolster domestic API manufacturing. This initiative aims to reduce reliance on imports by incentivizing local production of critical APIs and KSMs. However, the effectiveness of this scheme in achieving self-sufficiency remains to be fully realized, and the industry continues to monitor its progress closely.

The Sulfadoxine export market from India exhibits significant supplier concentration, with the top five exporters controlling 84.1% of the market. S KANT HEALTHCARE LIMITED alone accounts for 69.5% of exports, indicating a heavy reliance on a single supplier. Such concentration poses risks, as any operational disruptions within these key companies could lead to substantial supply shortages.

To mitigate these risks, the Indian government's PLI scheme, initiated in March 2020, aims to diversify and strengthen the domestic pharmaceutical manufacturing base. By encouraging the establishment of new manufacturing units and the expansion of existing ones, the scheme seeks to reduce dependency on a limited number of suppliers and enhance the resilience of the supply chain.

Recent geopolitical tensions have significantly impacted global shipping routes critical to pharmaceutical exports. In February 2026, the closure of the Strait of Hormuz due to escalating conflicts disrupted the movement of oil and other commodities, including pharmaceuticals. This disruption led to increased shipping costs and delays, affecting the timely delivery of essential medicines. Additionally, instability in the Red Sea and the Suez Canal has forced shipping companies to reroute vessels around the Cape of Good Hope, adding approximately 10 to 14 days to transit times and further escalating costs.

These disruptions have prompted regulatory bodies like the FDA to monitor and address potential drug shortages. The FDA actively works with industry stakeholders to identify and mitigate supply chain vulnerabilities, ensuring the continued availability of critical medications.

• Diversify Supplier Base: Encourage the development of additional domestic API and KSM manufacturers to reduce reliance on a limited number of suppliers.

• Enhance Domestic Production: Support initiatives like the PLI scheme to strengthen local manufacturing capabilities and achieve self-sufficiency in critical pharmaceutical components.

• Strengthen Supply Chain Monitoring: Implement robust systems to monitor supply chain dynamics and identify potential disruptions proactively.

• Develop Contingency Plans: Establish alternative shipping routes and logistics strategies to mitigate the impact of geopolitical tensions on transportation.

• Engage with Regulatory Bodies: Collaborate with organizations like the FDA to stay informed about potential shortages and participate in coordinated response efforts.

RISK_LEVEL: MEDIUM